Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · IEX Real-Time Price · USD
15.39
-0.62 (-3.87%)
At close: May 2, 2024, 4:00 PM
16.00
+0.61 (3.96%)
After-hours: May 2, 2024, 7:57 PM EDT
Avalo Therapeutics Revenue
In the year 2023, Avalo Therapeutics had annual revenue of $1.92M, a decrease of -89.34%. Revenue in the quarter ending December 31, 2023 was $571.00K, a -36.27% decrease year-over-year.
Revenue (ttm)
$1.92M
Revenue Growth
-89.34%
P/S Ratio
8.27
Revenue / Employee
$101,263
Employees
19
Market Cap
15.92M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.92M | -16.13M | -89.34% |
Dec 31, 2022 | 18.05M | 12.65M | 234.40% |
Dec 31, 2021 | 5.40M | -1.30M | -19.42% |
Dec 31, 2020 | 6.70M | -51.35K | -0.76% |
Dec 31, 2019 | 6.75M | -278.03K | -3.96% |
Dec 31, 2018 | 7.03M | -20.78M | -74.73% |
Dec 31, 2017 | 27.81M | 26.66M | 2,312.27% |
Dec 31, 2016 | 1.15M | - | - |
Dec 31, 2015 | 0 | - | - |
Dec 31, 2014 | 0 | - | - |
Dec 31, 2013 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ATI Physical Therapy | 699.02M |
CareCloud | 117.06M |
Flora Growth | 76.07M |
Streamline Health Solutions | 23.98M |
Akso Health Group | 2.20M |
Talphera | 651.00K |
Orgenesis | 530.00K |
AVTX News
- 4 weeks ago - Avalo Therapeutics Appoints Biotech Leaders to Board of Directors - GlobeNewsWire
- 4 weeks ago - Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip? - Invezz
- 4 weeks ago - Avalo Reports 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces 1-for-240 Reverse Stock Split - GlobeNewsWire
- 5 months ago - Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split - GlobeNewsWire
- 6 months ago - Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates - GlobeNewsWire
- 6 months ago - Avalo Completes Divestiture of AVTX-800 Series - GlobeNewsWire